Bestatin attenuates breast cancer stemness by targeting puromycin-sensitive aminopeptidase

Area of Science:

• Oncology
• Cancer Stem Cell Biology

Background:

• Breast cancer is a leading cause of cancer-related mortality in women, with increasing incidence.
• Breast cancer stem cells (BCSCs) drive tumor progression and therapeutic resistance.
• Bestatin is an investigational adjuvant chemotherapy agent known to induce apoptosis.

Purpose of the Study:

• To investigate the effects of bestatin on breast cancer stem cells (BCSCs).
• To evaluate bestatin's potential in overcoming drug resistance and tumor advancement.
• To explore novel therapeutic strategies for breast cancer treatment.

Main Methods:

• Sorted BCSCs from breast cancer cell lines were treated with bestatin.
• In vitro and in vivo experiments were conducted to assess bestatin's impact.
• Puromycin-sensitive aminopeptidase's role in cell cycle regulation was examined.

Main Results:

• Bestatin significantly inhibited the migration and proliferation of breast cancer cells.
• Bestatin reduced the stemness of BCSCs both in vitro and in vivo.
• Puromycin-sensitive aminopeptidase mediated increased apoptosis and reduced proliferation in BCSCs.

Conclusions:

• Targeting cancer stem cells, specifically BCSCs, presents a promising therapeutic avenue.
• Bestatin demonstrates potential as a novel treatment strategy for breast cancer.
• The study suggests new therapeutic approaches for breast cancer patients by targeting stemness.